Iceland· IS-EU/1/02/203/005-007
Kineret
A anakinra product containing anakinra inn, registered in Iceland by *Swedish Orphan Biovitrum AB (publ). The same ATC class is registered in 13 of our 19 countries.
Checked against Icelandic Medicines Agency (Iceland) on
Informational only — not a medical device.
Where it is registered
Anakinra is registered in 13 of 19 countries.
Countries holding a registration under ATC L04AC03 (anakinra), each read from that country’s own register.
- This record: Iceland, from Icelandic Medicines Agency (Iceland)
- 8 of them publish a price we can compare per daily dose
Anakinra · ATC L04AC03
13 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- United Kingdom
- United Statesprice
The record
At a glance
Icelandic Medicines Agency (Iceland)- Active substance
- Anakinra INN
- Manufacturer
- *Swedish Orphan Biovitrum AB (publ)
- Country
- Iceland (IS)
- ATC code
- L04AC03
- ATC class
- Anakinra
- Defined daily dose
- 0.1 g, P
- Reimbursed
- Not published by this register
- Source register
- Icelandic Medicines Agency (Iceland)
- Last checked
- September 29, 2026
Packs & prices · 1
1 priced- ean4186420,67 ml x7 sprISK 37405
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
375 interactions on record for anakinra.
Graded by severity as the source publishes them — 31 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Anakinra · interactions on record
375 records
- 31 severe
- 337 moderate
- 7 minor
Most severe, free to view
- CladribineL01BB04severe
- PrednisoloneA07EA01moderate
- HydrocortisoneA07EA02moderate
- PrednisoneA07EA03moderate
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Anakinra in 14 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaKINERETSwedish Orphan Biovitrum AB (publ), Stockholm
- BelgiumKineret 100 mg/0.67 mlSwedish Orphan Biovitrum (Publ)
- SpainKINERET 100 mg/0,67 ml solucion inyectable en jeringa precargadaSwedish Orphan Biovitrum Ab (Publ)
- PolandKineretSwedish Orphan Biovitrum AB
- SwedenKineret 100 mg/0,67 ml Injektionsvätska, lösning i förfylld sprutaSwedish Orphan Biovitrum AB (publ)
- FinlandKineretSwedish Orphan Biovitrum AB (publ)
- FranceKINERET 100 mg/0,67 mL, solution injectable en seringue préremplieSWEDISH ORPHAN BIOVITRUM INTERNATIONAL (SUEDE)
- United KingdomKineret 100mg/0.67ml solution for injection pre-filled syringesSwedish Orphan Biovitrum Ltd
Authorised across Europe · EMA
The same active substance is authorised in 2 EEA countries. Names it is sold under:
- Liechtenstein · Kineret
- Norway · Kineret
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Icelandic Medicines Agency (Iceland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/4a514add-c22f-4bff-b245-1b9318d1fc1d GET /v1/drugs/4a514add-c22f-4bff-b245-1b9318d1fc1d?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Stungulyf, lausn í áfylltri sprautu",
"source": "lyfjastofnun",
"atc_raw": "L04AC03",
"marketed": true,
"strength": "100 mg/0,67 ml",
"ma_number": "EU/1/02/203/005-007",
"substance": "Anakinra INN",
"other_info": "Ávísun lyfsins er bundin við sérfræðinga í lungnalækningum, smitsjúkdómum, ofnæmissjúkdómum og gigtarsjúkdómum og barnalækna með sérþekkingu á gigtarsjúkdómum og ónæmissjúkdómum.\r\nMarkaðssetning á Íslandi er háð því að Lyfjastofnun hafi staðfest að sérstök skilyrði er varða öryggi og verkun við notkun lyfsins séu uppfyllt.",
"legal_status": "(R Z) Sérfræðingsmerkt (og lyfseðilsskylt)",
"ma_issued_serial": "41593"
}See everything about anakinra.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.